<DOC>
	<DOCNO>NCT02427308</DOCNO>
	<brief_summary>The purpose observational study fulfill FDA Post Marketing Requirement ( PMR ) 2127-1 miltefosine ( NDA204684 ) : implement pregnancy registry time period Mar 2015-Mar 2024 . This study prospective observational study female patient undergo Impavido become pregnant treatment within 5 month complete treatment volunteer provide information pregnancy outcome pregnancy .</brief_summary>
	<brief_title>Treatment Leishmaniasis With ImpavidoÂ® ( Miltefosine ) : Pregnancy Registry</brief_title>
	<detailed_description>Objective : The purpose observational study fulfill FDA Post Marketing Requirement ( PMR ) 2127-1 miltefosine ( NDA204684 ) : implement pregnancy registry time period Mar 2015-Mar 2024 . Study Design : This study prospective observational study female patient undergo Impavido become pregnant treatment within 5 month complete treatment volunteer provide information pregnancy outcome pregnancy . Information collect patient 's provider Impavido treatment , obstetrical treatment , applicable , child 's pediatrician . Population : Leishmaniasis patient patient take Impavido off-label become pregnant take Impavido within 5 month take Impavido . Drug Product : Drug name : Impavido ( 50 mg capsule ) . Dosing regimen : per Impavido Product Label ( PL ) Study Procedures : Pregnant woman become aware Impavido Pregnancy Registry via product label ( PL ) Impavido website physician . By call 1-866-588-5405 , patient connect Impavido Pregnancy Registry Coordinating Center . A trained staff member acquaint patient goal procedure study . If patient tentatively agree participate study telephone , patient mail information form , Consent Form Assent Form appropriate , Consent patient 's physician obstetrician child 's pediatrician release medical information . Receipt four sign Consent Forms Assent Form appropriate Coordinating Center signify patient and/or legal guardian consent/assent . The Coordinating Center contact patient and/or patient 's physician trimester delivery collect data maternal adverse event ( AEs ) , pregnancy outcome , fetal outcome . Sample Size And Study Duration : Estimated 0-1 patient per year 10 year . Outcome Parameters : Maternal AEs . Pregnancy outcome . Fetal outcome . Analysis Plan : Baseline data , compliance prescribe treatment , outcomes report individual patient patient .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>1 . Has subject receive Impavido ? 2 . Is subject female ? 3 . Did subject become pregnant Impavido treatment within 5 month complete treatment ? 4 . Did subject legal guardian give consent/assent study collect data physician ? [ none ]</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>leishmaniasis</keyword>
	<keyword>miltefosine</keyword>
	<keyword>pregnancy</keyword>
</DOC>